Insert Link Medical Formulary Strategy ensures the most appropriate and clinically effective medical benefit drugs are evaluated with product-preferencing strategies, for all lines of business....

Cover image Specialty insights to watch Prime Therapeutics /summer-2026-prime-therapeutics-report The Summer 2026 Prime Therapeutics Report delivers practical insights on the therapies, trends and...

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Clinical deep dive Disease state overview WAS is a rare, X-linked, genetic disorder characterized by thrombocytopenia, eczema, immunodeficiency, and increased risk of autoimmunity and...

All brand names are property of their respective owners. References Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333(21):1906-1917. doi:10.1001/jama.2025.0560...

Last year, Oncology Insights brought you the most talked about topics in 2024. As we enter this new year, let us review these impactful and potentially practicing changing subjects that are likely...

Methodological Framework for Propensity Adjusted Benchmarks for Pharmacy Key Performance Indicators The purpose of the study was to create a methodological framework for using propensity score...

Clinical deep dive Disease state overview Myelodysplastic syndromes (MDS) are classified as disorders in which there are abnormal (dysplastic) hematopoietic stem cells in the bone marrow, leading...

Whitepaper Tab 1 Myth 1 Myth 2 Myth 3 Myth 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed nec ornare mi. Praesent ultrices ipsum eget est rutrum, eget congue orci molestie. Sed diam...

For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories

Empowering client, providers and members Building a trusted, transparent PBM Tab 1 2021 – Current 2015 – 2020 2010 – 2014 1998 – 2009 Helping improve care, reducing cost through integration See our...

Clinical deep dive Disease state overview MacTel type 2 is a rare neurodegenerative disease that affects the macula, which processes central and color vision. It is a bilateral asymmetric...

Publications High Cost Therapy Profile: October 2024 Eladocagene Exuparvovec October 15, 2024 References PTC Therapeutics announces FDA acceptance and Priority Review of the BLA for UpstazaTM. PTC...

Prime is pleased to present the seventh edition of the Employer Market Insights Report. Within this one-of-a-kind publication, you’ll find critical pharmacy trend insights that will help you make...

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Marquee event showcased new Prime, our energy, ambition and transformative journey

Eyebrow High-Cost Therapy Profile: August 2024 Detailed information about intravenous (IV) linvoseltamab Oncology Linvoseltamab, intravenous (IV) Regeneron Pharmaceuticals Proposed indications...

Home Our solutions Modern technology MyRxInsights Our advanced analytics platform helps boost your clinical impact and drive down costs by delivering descriptive, diagnostic, predictive and...

When you fill your specialty prescription, we automatically enroll you in our Care Specialists program. Our care specialists are pharmacists and nurses who are specially trained in your condition....

Research awards AMCP Silver Award – Controlled Substances Triple Threat Overlapping Days: Relationship with Healthcare Utilization and Costs Academy of Managed Care Pharmacy: Annual Meeting AMCP...